GLP-3R Research: GLP-1, GIP & Glucagon Receptor Triple Agonism

GLP-3R research focuses on triple-receptor peptide pharmacology involving GLP-1R, GIPR, and the glucagon receptor (GCGR). Retatrutide is a well-characterized example of a single peptide engineered to activate all three class B1 GPCR systems.

This article concentrates on the molecular and structural questions behind triple agonism: receptor recognition, Gs/cAMP signaling, relative receptor potency, structural determinants, and the experimental controls needed to interpret a multi-receptor peptide.

Three Receptors, One Research Peptide

Retatrutide has demonstrated agonist activity at GLP-1R, GIPR, and GCGR. That makes it useful for studying how a single engineered peptide can engage three related receptors while producing distinct potency and interaction profiles at each target.

Structural Basis of Triple Agonism

Published cryo-EM research has visualized retatrutide bound to GLP-1R, GIPR, and GCGR in active Gs-coupled complexes. Those structures identify receptor-specific peptide contacts and show how shared sequence features can support recognition across three related receptor pockets.

Gs and cAMP as Core Assay Endpoints

All three receptor systems can signal through Gs, making cAMP accumulation an important comparative endpoint. Researchers can pair cAMP assays with receptor-binding, beta-arrestin, internalization, and kinetic measurements to distinguish apparent potency from pathway-specific signaling behavior.

Research Questions for GLP-3R Systems

• What is the relative potency at GLP-1R, GIPR, and GCGR?
• Which peptide residues contribute most to each receptor interaction?
• How does receptor density influence apparent potency?
• Are signaling kinetics consistent across the three receptors?
• How do structural modifications affect stability and multi-receptor activity?
• Can receptor-selective controls separate the contribution of each pathway?

Primary Research References

• Structural insights into triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.
• Phase 2 research on retatrutide as a GIP, GLP-1 and glucagon receptor agonist.

Research Use Only: This content is limited to scientific and laboratory discussion. Products referenced are not intended for human consumption, medical use, veterinary use, or diagnostic use.

Explore more in the Revolt Peptides Research Journal.